Comparative Pharmacology
Head-to-head clinical analysis: CIPROFLOXACIN IN DEXTROSE 5 versus GEMIFLOXACIN MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPROFLOXACIN IN DEXTROSE 5 versus GEMIFLOXACIN MESYLATE.
CIPROFLOXACIN IN DEXTROSE 5% vs GEMIFLOXACIN MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with bacterial DNA replication, transcription, repair, and recombination.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, blocking DNA replication and transcription.
400 mg IV every 8 hours.
320 mg orally once daily for 7-14 days
None Documented
None Documented
Terminal elimination half-life 3.5-5 hours in healthy adults, prolonged to 6-10 hours in elderly or mild renal impairment, and up to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life 7–9 hours (mean 8.2 h) in healthy adults; prolonged in renal impairment (e.g., 15–22 h in severe renal impairment).
Renal excretion accounts for approximately 50-70% of an administered dose as unchanged drug; biliary/fecal excretion accounts for about 20-35% (including active drug and metabolites).
Renal: ~61% as unchanged drug, ~7% as glucuronide; Fecal/biliary: ~28% as unchanged drug and metabolites.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic